Felix Feng
Dr. Felix Feng is the George and Judy Marcus Distinguished Professor of Radiation Oncology, Urology, and Medicine and Vice Chair of the Department of Radiation Oncology at the University of California at San Francisco (UCSF). He serves as the Executive Director of the Benioff Initiative for Prostate Cancer Research, a UCSF-wide initiative focused on translational research for prostate cancer, and also serves as the Associate Director for Translational Research for the Helen Diller Family Comprehensive Cancer Center at UCSF. Additionally, Dr. Feng chairs the Genitourinary Cancer Committee for NRG Oncology, an international clinical trials group focused on cancer, and is a member of the NCI Genitourinary Cancer Steering Committee. He is a physician-scientist whose research interests include 1) the identification of biomarkers of treatment response or resistance in genitourinary cancers and 2) the development of rational approaches of targeted treatment for therapy-resistant disease. Dr. Feng’s laboratory utilizes high-throughput approaches to interrogate patient samples from clinical trials. His group developed the first clinical-grade biomarker panels that predict prostate cancer response to post-operative radiation (Zhao et al, Lancet Oncology 2016) and androgen deprivation (Zhao et al, JAMA Oncology 2017), and also identified a plasma-based cell-free DNA biomarker that predicts resistance to PARP1 inhibition (Quigley et al, Cancer Discovery 2017).
Abstracts this author is presenting: